☰

Xinli Liu, Ph.D. - Publications

Affiliations: 
2004 University of Kentucky, Lexington, KY 
Area:
Analytical Chemistry, Pharmaceutical Chemistry, Pharmacology
Tree Info Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 La-Beck NM, Liu X, Shmeeda H, Shudde C, Gabizon AA. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. Seminars in Cancer Biology. PMID 31874280 DOI: 10.1016/J.Semcancer.2019.12.001  0.342
2019 La-Beck NM, Liu X, Wood LM. Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery. Frontiers in Pharmacology. 10: 220. PMID 30914953 DOI: 10.3389/Fphar.2019.00220  0.321
2018 Dong Z, Yu D, Liu Q, Ding Z, Lyons VJ, Bright RK, Pappas D, Liu X, Li W. Enhanced capture and release of circulating tumor cells using hollow glass microspheres with a nanostructured surface. Nanoscale. PMID 30160287 DOI: 10.1039/C8Nr04434A  0.324
2016 Liu X, Hye T. Abstract 2163: Targeting brain tumor and brain metastases using brain penetrating peptide and long circulating nanoemulsions Cancer Research. 76: 2163-2163. DOI: 10.1158/1538-7445.Am2016-2163  0.309
2016 Fofaria N, Ranjan A, Qhattal HSS, Liu X, Srivastava SK. Abstract 2062: Nanoemulsion formulations for anticancer agent piplartine characterization, toxicological, pharmacokinetics and efficacy studies Cancer Research. 76: 2062-2062. DOI: 10.1158/1538-7445.Am2016-2062  0.335
2016 Tang S, Jiang P, Liu X. Abstract 1536: In silico discovery of target genes and pathways associated with breast cancer brain and bone metastases Cancer Research. 76: 1536-1536. DOI: 10.1158/1538-7445.Am2016-1536  0.302
2015 Fofaria NM, Qhattal HS, Liu X, Srivastava SK. Nanoemulsion formulations for anti-cancer agent piplartine - characterization, toxicological, pharmacokinetics and efficacy studies. International Journal of Pharmaceutics. PMID 26642946 DOI: 10.1016/J.Ijpharm.2015.11.045  0.325
2014 Liu X, Qhattal HSS, Hye T. Abstract 5405: Self-emulsifying nanoemulsions target intracranial glioblastoma tumors:In vivooptical imaging and fluorescence microscopy evidences Cancer Research. 74: 5405-5405. DOI: 10.1158/1538-7445.Am2014-5405  0.325
2013 Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, Qhattal HS, Geldenhuys WJ, Palmieri D, Steeg PS, Smith QR, Lockman PR. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Molecular Cancer Therapeutics. 12: 2389-99. PMID 24002934 DOI: 10.1158/1535-7163.Mct-13-0132  0.346
2013 Wang X, Wu E, Wu J, Wang TL, Hsieh HP, Liu X. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells. Plos One. 8: e65686. PMID 23762410 DOI: 10.1371/Journal.Pone.0065686  0.301
2013 de Pace RC, Liu X, Sun M, Nie S, Zhang J, Cai Q, Gao W, Pan X, Fan Z, Wang S. Anticancer activities of (-)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. Journal of Liposome Research. 23: 187-96. PMID 23600473 DOI: 10.3109/08982104.2013.788023  0.336
2012 Liu L, Beck H, Wang X, Hsieh HP, Mason RP, Liu X. Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts. Plos One. 7: e43314. PMID 22937031 DOI: 10.1371/Journal.Pone.0043314  0.345
2011 Qhattal HS, Wang S, Salihima T, Srivastava SK, Liu X. Nanoemulsions of cancer chemopreventive agent benzyl isothiocyanate display enhanced solubility, dissolution, and permeability. Journal of Agricultural and Food Chemistry. 59: 12396-404. PMID 22011260 DOI: 10.1021/Jf202612B  0.332
2011 Hu J, Liu X, Hughes D, Esteva FJ, Liu B, Chandra J, Li S. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis. Plos One. 6: e23270. PMID 21853100 DOI: 10.1371/Journal.Pone.0023270  0.325
2011 Hu J, Liu X, Huang Q, Zhang B, Hughes DP, Chandra J, Xia X, Li S. Abstract 4559: Herceptin trimers linked by EDC could boost direct tumor cell death and overcome resistance to trastuzumab treatment via programmed tumor cell necrosis Cancer Research. 71: 4559-4559. DOI: 10.1158/1538-7445.Am2011-4559  0.336
2009 Liu X, Wang X, Tedjarati S, Wang T, Hsieh H. Abstract C234: A novel microtubule inhibitor BPR0L075 overcomes paclitaxel resistance in ovarian cancer cell lines Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C234  0.324
Show low-probability matches.